The Institut Bordet Clinical Cellular Therapy Research Laboratory (LTCC) is dedicated to fundamental and translational research in the fields of haematology and immunology cellular therapy.
The LTCC’s main objectives concern:
- study of the interaction between leukaemic cells and their microenvironment;
- establishment of new prognostic factors;
- development of new therapeutic strategies.
Within the field of cellular therapy, the LTCC is studying the functional characterisation of mesenchymal stromal cells obtained from different tissues and their manipulation with a view to increasing their therapeutic potential.
The LTCC is seeking to improve understanding of the physiopathology of chronic lymphoid leukaemia. We have identified new cellular, molecular and epigenetic biomarkers that help to refine patient prognosis and to guide the direction of treatment. An important part of our research focuses on the interaction between leukaemic cells and their microenvironment (via direct contact or via extracellular vesicles), involved in the progression of the disease and on means of interrupting this dialogue.
In the context of cellular therapy, the LTCC has characterised mesenchymal stromal cells (MSCs) from different tissue sources such as bone marrow, adipose tissue, umbilical cord, skin and muscle. The Laboratory’s key interest is the mechanisms involved in the regulation of the different actors of immune response by MSCs and is developing methods to improve the therapeutic effects of MSCs. Research is also aimed at developing acellular systems based on the capacity of MSCs to release extracellular vesicles capable of mimicking their effects. These extracellular vesicles will be characterised in terms of transcriptome, miRNome and proteome.
Cellular therapy pilot studies are also initiated in collaboration with clinical teams after agreement by the Institut Bordet ethics committee.
The LTCC is involved in training students from the Faculty of Medicine, of Biomedical and Pharmaceutical Sciences and from the Hautes Écoles. Students are supervised as part of immersion courses, for their final dissertation and when completing a 4-year doctoral thesis. We are also involved in supervising theses by students from other universities.
IMPACT OF CHRONIC LYMPHOCYTIC LEUKEMIA-DERIVED EXTRACELLULAR VESICLES ON THE MICROENVIRONMENT IMMUNE LANDSCAPE / IMPACT DES VÉSICULES EXTRACELLULAIRES DÉRIVÉES DE LEUCÉMIE LYMPHOÏDE CHRONIQUE SUR LES CELLULES IMMUNITAIRES DU MICROENVIRONNEMENT
Immunosuppressive microenvironment in multiple myeloma: role of bone marrow-mesenchymal cell (BM-MSC) glycosylation
Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Natural Nanocarriers: Concise Review.
Authors : Draguet F, Bouland C, Dubois N, Bron D, Meuleman N, Stamatopoulos B, Lagneaux L
Year : 2023
Journal : Pharmaceutics
Volume : 15
Bioscreening and pre-clinical evaluation of the impact of bioactive molecules from Ptychotis verticillata on the multilineage potential of mesenchymal stromal cells towards immune- and inflammation-mediated diseases.
Authors : Bouhtit F, Najar M, Rahmani S, Melki R, Najimi M, Sadki K, Boukhatem N, Twizere JC, Meuleman N, Lewalle P, Lagneaux L, Merimi M
Year : 2022
Journal : Inflamm Res
Volume : 71
Pages : 887-898
Suburethral implantation of autologous regenerative cells for female stress urinary incontinence management: Results of a pilot study.
Authors : Maene A, Deniz G, Bouland C, Lagneaux L, Philippart P, Buxant F
Year : 2022
Journal : Eur J Obstet Gynecol Reprod Biol
Volume : 278
Pages : 38-44
Mesenchymal Stem/Stromal Cells as a Therapeutic Tool in Cell-Based Therapy and Regenerative Medicine: An Introduction Expertise to the Topical Collection.
Authors : Merimi M, Fahmi H, De Kock J, Beguin C, Burny A, Moll G, Poggi A, Najar M
Year : 2022
Journal : Cells
Volume : 11
Extracellular vesicle secretion by leukemia cells in vivo promotes CLL progression by hampering antitumor T-cell responses.
Authors : Gargiulo E, Viry E, Morande PE, Largeot A, Gonder S, Xian F, Ioannou N, Benzarti M, Kleine Borgmann FB, Mittelbronn M, Dittmar G, Nazarov PV, Meiser J, Stamatopoulos B, Ramsay AG, Moussay E, Paggetti J
Year : 2022
Journal : Blood Cancer Discov